Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
808.00    -10.00 (-1.22%)
Bid:
811.00
Ask:
813.00
Spread: 2.00 (0.247%)
Market Cap: £1.12b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Acquisition

28 Jul 2017 12:20

RNS Number : 4554M
Savills PLC
28 July 2017
 

SAVILLS ACQUISITION OF AGUIRRE NEWMAN

 

Further building the scale of Savills European real estate services business

 

Savills plc, one of the world's leading real estate advisory firms, announces the proposed acquisition of Aguirre Newman S.A. ("Aguirre Newman"), the leading Spanish independent real estate advisory business, for up to €67 million payable in instalments over five years from completion. The acquisition is scheduled to complete by 30th November 2017 following satisfaction of customary regulatory and closing conditions.

 

Aguirre Newman was founded in 1988. The business employs more than 400 staff and is headquartered in Madrid, with offices in Barcelona, Malaga, Lisbon and Porto (Portugal). The firm provides agency, investment, management, architectural, consultancy, valuation, planning, corporate finance and asset management services.

 

The businesses of Aguirre Newman and Savills in Spain will be integrated with Savills existing Spanish business employing 70 people in offices in Madrid and Barcelona, and will initially operate in Spain under the Savills Aguirre Newman brand. The principals of Aguirre Newman, Santiago Aguirre and Stephen Newman, and the Head of Savills Spain, Rafael Merry del Val, will be appointed to the Board of the combined businesses.

 

Commenting on the acquisition, Jeremy Helsby, Savills CEO, said: "The acquisition of Aguirre Newman combined with our existing Spanish business provides us with a significant footprint in Spain, a market where we see exciting long term growth opportunities. It follows Savills strategy to develop multi-service offerings and expand our presence in key Continental European markets."

 

For the year ended 31 December 2016, the gross turnover of the continuing operations of Aguirre Newman was €69 million.

 

The purchase consideration will be funded from Savills cash and existing banking facilities. On completion, Savills will pay €42 million. Deferred consideration of up to €5 million is payable on each anniversary of completion for the next five years totalling €25 million.

 

 

 

For further information please contact:

 

Savills

Jeremy Helsby, Chief Executive Officer, Tel: +44 20 7409 8934

Simon Shaw, Chief Financial Officer

 

Tulchan Communications Tel: +44 20 7353 4200

Peter Hewer

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQOKFDDDBKDOOB
Date   Source Headline
1st Jun 202611:29 amRNSTotal Voting Rights
22nd May 202610:09 amRNSDirector/PDMR Shareholding
14th May 202612:41 pmRNSResult of AGM
13th May 20264:16 pmRNSResult of AGM
13th May 20267:00 amRNSAGM Statement
12th May 20263:41 pmRNSDirector/PDMR Shareholding
7th May 20263:39 pmRNSDirector Declaration
29th Apr 20263:04 pmRNSReplacement - Director/PDMR Shareholding
29th Apr 20261:23 pmRNSDirector/PDMR Shareholding
28th Apr 20261:58 pmRNSDirector/PDMR Shareholding
13th Apr 20265:24 pmRNSHolding(s) in Company
13th Apr 20262:10 pmRNSDirector/PDMR Shareholding
7th Apr 20264:03 pmRNSAnnual Report and AGM Notice
1st Apr 202610:00 amRNSTotal Voting Rights
31st Mar 202612:55 pmRNSDirector/PDMR Shareholding
26th Mar 20268:57 amRNSDirector/PDMR Shareholding
24th Mar 202611:02 amRNSDirector/PDMR Shareholding
23rd Mar 20269:27 amRNSDirector/PDMR Shareholding
18th Mar 20263:47 pmRNSDirector/PDMR Shareholding
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
13th Mar 20261:34 pmRNSDirector/PDMR Shareholding
13th Mar 20261:32 pmRNSDirector/PDMR Shareholding
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:08 amRNSFinal Results
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
5th Mar 20265:00 pmRNSHolding(s) in Company
2nd Mar 20269:11 amRNSTotal Voting Rights
25th Feb 202611:14 amRNSHolding(s) in Company
11th Feb 20264:07 pmRNSDirector/PDMR Shareholding
4th Feb 20265:29 pmRNSHolding(s) in Company
2nd Feb 20265:32 pmRNSTotal Voting Rights
19th Jan 20268:30 amRNSDirectorship change
15th Jan 20267:00 amRNSYear End Trading Update
13th Jan 20265:40 pmRNSDirector/PDMR Shareholding
13th Jan 202612:59 pmRNSHolding(s) in Company
2nd Jan 20263:00 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
1st Dec 20259:49 amRNSTotal Voting Rights
11th Nov 20254:58 pmRNSDirector/PDMR Shareholding
3rd Nov 202512:32 pmRNSTotal Voting Rights
13th Oct 20251:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.